{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:22:55Z","timestamp":1787030575125,"version":"build-2736575974"},"reference-count":122,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2022.13530","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T07:43:39Z","timestamp":1664264619000},"source":"Crossref","is-referenced-by-count":13,"title":["The immune landscape of hepatocellular carcinoma\u2011where we are? (Review)"],"prefix":"10.3892","volume":"24","author":[{"given":"Maciej","family":"Gryziak","sequence":"first","affiliation":[{"name":"Department of Oncology, Medical University of Warsaw, 02\u2011091 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Wozniak","sequence":"additional","affiliation":[{"name":"Department of Oncology, Medical University of Warsaw, 02\u2011091 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leszek","family":"Kraj","sequence":"additional","affiliation":[{"name":"Department of Oncology, Medical University of Warsaw, 02\u2011091 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letycja","family":"Rog","sequence":"additional","affiliation":[{"name":"Department of Oncology, Medical University of Warsaw, 02\u2011091 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafal","family":"Stec","sequence":"additional","affiliation":[{"name":"Department of Oncology, Medical University of Warsaw, 02\u2011091 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2022,9,27]]},"reference":[{"key":"key20221013104825_b1-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"key20221013104825_b2-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"key20221013104825_b3-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"key20221013104825_b4-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"ix183","DOI":"10.1093\/annonc\/mdz446.002","article-title":"Imbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)'","volume":"30","author":"Cheng","year":"2019","journal-title":"Ann Oncol"},{"key":"key20221013104825_b5-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/jcar.JCar_9_16","article-title":"Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis","volume":"16","author":"Ghouri","year":"2017","journal-title":"J Carcinog"},{"key":"key20221013104825_b6-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1134\/S0006297917080016","article-title":"Components of the hepatocellular carcinoma microenvironment and their role in tumor progression","volume":"82","author":"Novikova","year":"2017","journal-title":"Biochemistry (Mosc)"},{"key":"key20221013104825_b7-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/s13238-020-00748-0","article-title":"Gut microbiota alterations are distinct for primary colorectal cancer and hepatocellular carcinoma","volume":"12","author":"Jia","year":"2021","journal-title":"Protein Cell"},{"key":"key20221013104825_b8-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","article-title":"The nature of myeloid-derived suppressor cells in the tumor microenvironment","volume":"37","author":"Kumar","year":"2016","journal-title":"Trends Immunol"},{"key":"key20221013104825_b9-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41467-017-00530-7","article-title":"Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2\/CD39L1 in hepatocellular carcinoma","volume":"8","author":"Chiu","year":"2017","journal-title":"Nat Commun"},{"key":"key20221013104825_b10-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1053\/j.gastro.2008.03.020","article-title":"A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells","volume":"135","author":"Hoechst","year":"2008","journal-title":"Gastroenterology"},{"key":"key20221013104825_b11-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.ccr.2004.08.031","article-title":"Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis","volume":"6","author":"Yang","year":"2004","journal-title":"Cancer Cell"},{"key":"key20221013104825_b12-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"240","DOI":"10.4049\/jimmunol.182.1.240","article-title":"Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1","volume":"182","author":"Li","year":"2009","journal-title":"J Immunol"},{"key":"key20221013104825_b13-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1136\/gutjnl-2014-307671","article-title":"Tim-3 fosters HCC development by enhancing TGF-\u03b2-mediated alternative activation of macrophages","volume":"64","author":"Yan","year":"2015","journal-title":"Gut"},{"key":"key20221013104825_b14-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1002\/ijc.31216","article-title":"Targeting tumor-infiltrating Ly6G+ myeloid cells improves sorafenib efficacy in mouse orthotopic hepatocellular carcinoma","volume":"142","author":"Chang","year":"2018","journal-title":"Int J Cancer"},{"key":"key20221013104825_b15-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/0167-5699(92)90008-U","article-title":"The origin and function of tumor-associated macrophages","volume":"13","author":"Mantovani","year":"1992","journal-title":"Immunol Today"},{"key":"key20221013104825_b16-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1038\/nri1733","article-title":"Monocyte and macrophage heterogeneity","volume":"5","author":"Gordon","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"key20221013104825_b17-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"13","DOI":"10.12703\/P6-13","article-title":"The M1 and M2 paradigm of macrophage activation: Time for reassessment","volume":"6","author":"Martinez","year":"2014","journal-title":"F1000Prime Rep"},{"key":"key20221013104825_b18-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.cellsig.2013.11.004","article-title":"Macrophage polarization and function with emphasis on the evolving roles of coordinated regulation of cellular signaling pathways","volume":"26","author":"Zhou","year":"2014","journal-title":"Cell Signal"},{"key":"key20221013104825_b19-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1189\/jlb.0609385","article-title":"Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation","volume":"86","author":"Solinas","year":"2009","journal-title":"J Leukoc Biol"},{"key":"key20221013104825_b20-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"792","DOI":"10.3389\/fimmu.2019.00792","article-title":"Macrophage polarization in physiological and pathological pregnancy","volume":"10","author":"Yao","year":"2019","journal-title":"Front Immunol"},{"key":"key20221013104825_b21-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1002\/hep.27867","article-title":"Myeloid cells in hepatocellular carcinoma","volume":"62","author":"Wan","year":"2015","journal-title":"Hepatology"},{"key":"key20221013104825_b22-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"4709","DOI":"10.1002\/cam4.2327","article-title":"Crosstalk between cancer and immune cells: Role of tumor-associated macrophages in the tumor microenvironment","volume":"8","author":"Wang","year":"2019","journal-title":"Cancer Med"},{"key":"key20221013104825_b23-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"44465","DOI":"10.18632\/oncotarget.17973","article-title":"M2 tumor-associated macrophages produce interleukin-17 to suppress oxaliplatin-induced apoptosis in hepatocellular carcinoma","volume":"8","author":"Guo","year":"2017","journal-title":"Oncotarget"},{"key":"key20221013104825_b24-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12935-019-0771-8","article-title":"Tumor-associated macrophages modulate resistance to oxaliplatin via inducing autophagy in hepatocellular carcinoma","volume":"19","author":"Fu","year":"2019","journal-title":"Cancer Cell Int"},{"key":"key20221013104825_b25-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1080\/08941939.2019.1631411","article-title":"Meta-analysis of the prognostic and clinical value of tumor-associated macrophages in hepatocellular carcinoma","volume":"34","author":"Zhang","year":"2021","journal-title":"J Invest Surg"},{"key":"key20221013104825_b26-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.3389\/fimmu.2019.01643","article-title":"M1 macrophages induce PD-L1 expression in hepatocellular carcinoma cells through IL-1\u03b2 signaling","volume":"10","author":"Zong","year":"2019","journal-title":"Front Immunol"},{"key":"key20221013104825_b27-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"e0223971","DOI":"10.1371\/journal.pone.0223971","article-title":"Clinicopathologic and prognostic significance of tumor-associated macrophages in patients with hepatocellular carcinoma: A meta-analysis","volume":"14","author":"Ding","year":"2019","journal-title":"PLoS One"},{"key":"key20221013104825_b28-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"14572","DOI":"10.1038\/ncomms14572","article-title":"Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice","volume":"8","author":"Lau","year":"2017","journal-title":"Nat Commun"},{"key":"key20221013104825_b29-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s00262-018-2263-4","article-title":"Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironment","volume":"68","author":"Umezu","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"key20221013104825_b30-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41416-019-0482-x","article-title":"M2 macrophages mediate sorafenib resistance by secreting HGF in a feed-forward manner in hepatocellular carcinoma","volume":"121","author":"Dong","year":"2019","journal-title":"Br J Cancer"},{"key":"key20221013104825_b31-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.3892\/ol.2017.6717","article-title":"Zoledronic acid inhibits infiltration of tumor-associated macrophages and angiogenesis following transcatheter arterial chemoembolization in rat hepatocellular carcinoma models","volume":"14","author":"Zhou","year":"2017","journal-title":"Oncol Lett"},{"key":"key20221013104825_b32-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1158\/1535-7163.MCT-16-0866","article-title":"Colony-stimulating factor 1 receptor blockade inhibits tumour growth by altering the polarization of tumour-associated macrophages in hepatocellular carcinoma","volume":"16","author":"Ao","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"key20221013104825_b33-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"286","DOI":"10.2174\/1871520616666160204112556","article-title":"8-bromo-7-methoxychrysin reversed M2 polarization of tumour-associated macrophages induced by liver cancer stem-like cells","volume":"17","author":"Sun","year":"2017","journal-title":"Anticancer Agents Med Chem"},{"key":"key20221013104825_b34-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1053\/j.gastro.2014.08.039","article-title":"Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells","volume":"147","author":"Wan","year":"2014","journal-title":"Gastroenterology"},{"key":"key20221013104825_b35-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/gutjnl-2015-310514","article-title":"Targeting of tumour-infiltrating macrophages via CCL2\/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma","volume":"66","author":"Li","year":"2017","journal-title":"Gut"},{"key":"key20221013104825_b36-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ebiom.2017.07.014","article-title":"A natural CCR93 antagonist relieves tumour-associated macrophage-mediated immunosuppression to produce a therapeutic effect for liver cancer","volume":"22","author":"Yao","year":"2017","journal-title":"EBioMedicine"},{"key":"key20221013104825_b37-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.jhep.2008.12.033","article-title":"Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients","volume":"50","author":"Zhang","year":"2009","journal-title":"J Hepatol"},{"key":"key20221013104825_b38-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1002\/hep.26731","article-title":"Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma","volume":"59","author":"Flecken","year":"2014","journal-title":"Hepatology"},{"key":"key20221013104825_b39-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41590-018-0044-z","article-title":"The immunology of hepatocellular carcinoma","volume":"19","author":"Ringelhan","year":"2018","journal-title":"Nat Immunol"},{"key":"key20221013104825_b40-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","article-title":"TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion","volume":"571","author":"Khan","year":"2019","journal-title":"Nature"},{"key":"key20221013104825_b41-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/ni.1679","article-title":"Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection","volume":"10","author":"Blackburn","year":"2009","journal-title":"Nat Immunol"},{"key":"key20221013104825_b42-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"key20221013104825_b43-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1053\/j.gastro.2018.08.030","article-title":"Association between expression level of PD1 by tumor-infiltrating CD8(+) T cells and features of hepatocellular carcinoma","volume":"155","author":"Kim","year":"2018","journal-title":"Gastroenterology"},{"key":"key20221013104825_b44-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1200\/JCO.2006.09.4565","article-title":"Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection","volume":"25","author":"Gao","year":"2007","journal-title":"J Clin Oncol"},{"key":"key20221013104825_b45-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1053\/j.gastro.2007.03.102","article-title":"Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients","volume":"132","author":"Fu","year":"2007","journal-title":"Gastroenterology"},{"key":"key20221013104825_b46-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"e1273309","DOI":"10.1080\/2162402X.2016.1273309","article-title":"PD-L1, Galectin-9 and CD8+ tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma","volume":"6","author":"Sideras","year":"2017","journal-title":"OncoImmunology"},{"key":"key20221013104825_b47-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jhep.2019.03.018","article-title":"Immunogenomic landscape of hepatocellular carcinoma with immune cell stroma and EBV-positive tumor-infiltrating lymphocytes","volume":"71","author":"Kang","year":"2019","journal-title":"J Hepatol"},{"key":"key20221013104825_b48-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1111\/liv.14192","article-title":"Immune landscape of hepatocellular carcinoma microenvironment: Implications for prognosis and therapeutic applications","volume":"39","author":"Cariani","year":"2019","journal-title":"Liver Int"},{"key":"key20221013104825_b49-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1053\/j.gastro.2016.02.040","article-title":"Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib","volume":"150","author":"Zhou","year":"2016","journal-title":"Gastroenterology"},{"key":"key20221013104825_b50-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1002\/hep.30630","article-title":"A positive feedback loop between cancer stem-like cells and tumor-associated neutrophils controls hepatocellular carcinoma progression","volume":"70","author":"Zhou","year":"2019","journal-title":"Hepatology"},{"key":"key20221013104825_b51-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1158\/1078-0432.CCR-09-2904","article-title":"Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects","volume":"16","author":"Zhang","year":"2010","journal-title":"Clin Cancer Res"},{"key":"key20221013104825_b52-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.7150\/thno.30958","article-title":"Acidic microenvironment up-regulates exosomal miR-21 and miR-10b in early-stage hepatocellular carcinoma to promote cancer cell proliferation and metastasis","volume":"9","author":"Tian","year":"2019","journal-title":"Theranostics"},{"key":"key20221013104825_b53-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"610513","DOI":"10.3389\/fonc.2020.610513","article-title":"Tumor immune microenvironment characterization in hepatocellular carcinoma identifies four prognostic and immunotherapeutically relevant subclasses","volume":"10","author":"Gao","year":"2021","journal-title":"Front Oncol"},{"key":"key20221013104825_b54-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1158\/2326-6066.CIR-21-0515","article-title":"Reversing T-cell exhaustion in cancer: Lessons learned from PD-1\/PD-L1 immune checkpoint blockade","volume":"10","author":"Budimir","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"key20221013104825_b55-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"e0212513","DOI":"10.1371\/journal.pone.0212513","article-title":"Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway","volume":"14","author":"Kato","year":"2019","journal-title":"PLoS One"},{"key":"key20221013104825_b56-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"105829","DOI":"10.1016\/j.phrs.2021.105829","article-title":"Lenvatinib enhances T cell immunity and the efficacy of adoptive chimeric antigen receptor-modified T cells by decreasing myeloid-derived suppressor cells in cancer","volume":"174","author":"Lu","year":"2021","journal-title":"Pharmacol Res"},{"key":"key20221013104825_b57-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"751159","DOI":"10.3389\/fonc.2021.751159","article-title":"Lenvatinib plus immune checkpoint inhibitors improve survival in advanced hepatocellular carcinoma: A Retrospective Study","volume":"11","author":"Huang","year":"2021","journal-title":"Front Oncol"},{"key":"key20221013104825_b58-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.3748\/wjg.v17.i28.3322","article-title":"Immunostaining of PD-1\/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma","volume":"17","author":"Wang","year":"2011","journal-title":"World J Gastroenterol"},{"key":"key20221013104825_b59-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"key20221013104825_b60-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1172\/JCI120803","article-title":"Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression","volume":"128","author":"Lin","year":"2018","journal-title":"J Clin Invest"},{"key":"key20221013104825_b61-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1002\/hep.28710","article-title":"Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features","volume":"64","author":"Calderaro","year":"2016","journal-title":"Hepatology"},{"key":"key20221013104825_b62-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","article-title":"Classifying cancers based on T-cell infiltration and PD-L1","volume":"75","author":"Teng","year":"2015","journal-title":"Cancer Res"},{"key":"key20221013104825_b63-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res"},{"key":"key20221013104825_b64-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1002\/hep.29904","article-title":"Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification","volume":"68","author":"Kurebayashi","year":"2018","journal-title":"Hepatology"},{"key":"key20221013104825_b65-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1111\/bcp.14316","article-title":"Mechanism-based treatment of cancer with immune checkpoint inhibitor therapies","volume":"86","author":"Abdou","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"key20221013104825_b66-ol-24-05-13530","article-title":"Bevacizumab, Avastin Summary of Product Characteristics","author":"European Medicine Agency"},{"key":"key20221013104825_b67-ol-24-05-13530","article-title":"Atezolizumab Summary of Product Characteristics","author":"European Medicine Agency"},{"key":"key20221013104825_b68-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1158\/1535-7163.MCT-09-0280","article-title":"Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts","volume":"8","author":"Roland","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"key20221013104825_b69-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1084\/jem.20140559","article-title":"VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors","volume":"212","author":"Voron","year":"2015","journal-title":"J Exp Med"},{"key":"key20221013104825_b70-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"key20221013104825_b71-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"key":"key20221013104825_b72-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"e204564","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: The checkmate 040 randomized clinical trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol"},{"key":"key20221013104825_b73-ol-24-05-13530","article-title":"Pembrolizumab Summary of Product Characteristics","author":"European Medicine Agency"},{"key":"key20221013104825_b74-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"key20221013104825_b75-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: A randomized, double-blind, phase III trial","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"key":"key20221013104825_b76-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1200\/JCO.20.03555","article-title":"Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: Randomized expansion of a phase I\/II study","volume":"39","author":"Kelley","year":"2021","journal-title":"J Clin Oncol"},{"key":"key20221013104825_b77-ol-24-05-13530","article-title":"Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (HIMALAYA)","volume-title":"ClinicalTrials.gov Identifier: NCT03298451","author":"U.S. National Library of Medicine (NIH)","year":"2017"},{"key":"key20221013104825_b78-ol-24-05-13530","article-title":"Combination Therapy of Microwave Ablation and Cellular Immunotherapy for Hepatocellular Carcinoma","volume-title":"ClinicalTrials.gov Identifier: NCT02851784","author":"U.S. National Library of Medicine (NIH)","year":"2016"},{"key":"key20221013104825_b79-ol-24-05-13530","article-title":"Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone (PHOCUS)","volume-title":"ClinicalTrials.gov Identifier: NCT02562755","author":"U.S. National Library of Medicine (NIH)","year":"2015"},{"key":"key20221013104825_b80-ol-24-05-13530","article-title":"FImmunotherapy for Advanced Liver Cancer (ALIVE)","volume-title":"ClinicalTrials.gov Identifier: NCT05033522","author":"U.S. National Library of Medicine (NIH)","year":"2021"},{"key":"key20221013104825_b81-ol-24-05-13530","article-title":"An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma","volume-title":"ClinicalTrials.gov Identifier: NCT02576509","author":"U.S. National Library of Medicine (NIH)","year":"2015"},{"key":"key20221013104825_b82-ol-24-05-13530","article-title":"RRFA+Highly-purified CTL vs. RFA Alone for Recurrent HCC","volume-title":"ClinicalTrials.gov Identifier: NCT02678013","author":"U.S. National Library of Medicine (NIH)","year":"2016"},{"key":"key20221013104825_b83-ol-24-05-13530","article-title":"Combination of Sintilimab and Stereotactic Body Radiotherapy in Hepatocellular Carcinoma (ISBRT01) (ISBRT01)","volume-title":"ClinicalTrials.gov Identifier: NCT04167293","author":"U.S. National Library of Medicine (NIH)","year":"2019"},{"key":"key20221013104825_b84-ol-24-05-13530","article-title":"Infusion of PD1\/PDL1 Inhibitor Via Hepatic Arterial Versus Vein for Immunotherapy of Advanced Hepatocellular Carcinoma","volume-title":"ClinicalTrials.gov Identifier: NCT03949231","author":"U.S. National Library of Medicine (NIH)","year":"2019"},{"key":"key20221013104825_b85-ol-24-05-13530","article-title":"DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma","volume-title":"ClinicalTrials.gov Identifier: NCT04229355","author":"U.S. National Library of Medicine (NIH)","year":"2020"},{"key":"key20221013104825_b86-ol-24-05-13530","article-title":"Efficacy and Safety of Immuncell-LC Group and Non-treatment Group in Hepatocelluar Carcinoma Patients","volume-title":"ClinicalTrials.gov Identifier: NCT00699816","author":"U.S. National Library of Medicine (NIH)","year":"2008"},{"key":"key20221013104825_b87-ol-24-05-13530","article-title":"Resection+Highly Purified CTL Versus Resection Alone for HCC","volume-title":"ClinicalTrials.gov Identifier: NCT02709070","author":"U.S. National Library of Medicine (NIH)","year":"2016"},{"key":"key20221013104825_b88-ol-24-05-13530","article-title":"Nivolumab in Combination With TACE\/TAE for Patients With Intermediate Stage HCC (TACE-3)","volume-title":"ClinicalTrials.gov Identifier: NCT04268888","author":"U.S. National Library of Medicine (NIH)","year":"2020"},{"key":"key20221013104825_b89-ol-24-05-13530","article-title":"Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 \/ KEYNOTE-937)","volume-title":"ClinicalTrials.gov Identifier: NCT03867084","author":"U.S. National Library of Medicine (NIH)","year":"2019"},{"key":"key20221013104825_b90-ol-24-05-13530","article-title":"Sintilimab Plus Bevacizumab as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Curative Resection (DaDaLi)","volume-title":"ClinicalTrials.gov Identifier: NCT04682210","author":"U.S. National Library of Medicine (NIH)","year":"2020"},{"key":"key20221013104825_b91-ol-24-05-13530","volume-title":"ClinicalTrials.gov Identifier NCT01749865","author":"U.S. National Library of Medicine (NIH):CIK Treatment for HCC Patient Underwent Radical Resection","year":"2012"},{"key":"key20221013104825_b92-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1002\/hep.31234","article-title":"Immunotherapy as a downstaging therapy for liver transplantation","volume":"72","author":"Schwacha-Eipper","year":"2020","journal-title":"Hepatology"},{"key":"key20221013104825_b93-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1111\/ajt.16448","article-title":"PD-1 inhibitor as bridge therapy to liver transplantation?","volume":"21","author":"Tabrizian","year":"2021","journal-title":"Am J Transplant"},{"key":"key20221013104825_b94-ol-24-05-13530","first-page":"317","article-title":"Adoptive Immunotherapy with Liver allograft-derived NK Cells Improves Recurrence-free Survival after Living-donor Liver Transplantation in Patients with Hepatocellular Carcinoma","volume":"15","author":"Tanimine","year":"2015","journal-title":"Am J Transplant"},{"key":"key20221013104825_b95-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2217\/imt-2020-0014","article-title":"Ipilumumab for hepatocellular cancer in a liver transplant recipient, with durable response, tolerance and without allograft rejection","volume":"12","author":"Pandey","year":"2020","journal-title":"Immunotherapy"},{"key":"key20221013104825_b96-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"163","DOI":"10.4251\/wjgo.v14.i1.163","article-title":"Immunotherapy in liver transplantation for hepatocellular carcinoma: Pros and cons","volume":"14","author":"Luo","year":"2022","journal-title":"World J Gastrointest Oncol"},{"key":"key20221013104825_b97-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"key20221013104825_b98-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"4102","DOI":"10.1200\/JCO.2016.67.2477","article-title":"Programmed Death-Ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma","volume":"34","author":"Daud","year":"2016","journal-title":"J Clin Oncol"},{"key":"key20221013104825_b99-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.7150\/thno.48027","article-title":"Assessing PD-L1 expression in non-small cell lung cancer and predicting responses to immune checkpoint inhibitors using deep learning on computed tomography images","volume":"11","author":"Tian","year":"2021","journal-title":"Theranostics"},{"key":"key20221013104825_b100-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1002\/cncr.32339","article-title":"Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma","volume":"125","author":"Feun","year":"2019","journal-title":"Cancer"},{"key":"key20221013104825_b101-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1002\/hep.29715","article-title":"Significance and mechanism of androgen receptor overexpression and androgen receptor\/mechanistic target of rapamycin cross-talk in hepatocellular carcinoma","volume":"67","author":"Zhang","year":"2018","journal-title":"Hepatology"},{"key":"key20221013104825_b102-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1093\/annonc\/mdu242","article-title":"Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer","volume":"25","author":"Azuma","year":"2014","journal-title":"Ann Oncol"},{"key":"key20221013104825_b103-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumour immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin Cancer Res"},{"key":"key20221013104825_b104-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"e00058","DOI":"10.14309\/ctg.0000000000000058","article-title":"Immunologic features of patients with advanced hepatocellular carcinoma before and during sorafenib or anti-programmed death-1\/programmed death-L1 treatment","volume":"10","author":"Macek Jilkova","year":"2019","journal-title":"Clin Transl Gastroenterol"},{"key":"key20221013104825_b105-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"e1325982","DOI":"10.1080\/2162402X.2017.1325982","article-title":"PD-L1 immune suppression in cancer: Tumor cells or host cells?","volume":"6","author":"Kleinovink","year":"2017","journal-title":"OncoImmunology"},{"key":"key20221013104825_b106-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"5024","DOI":"10.1158\/1078-0432.CCR-16-0698","article-title":"Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in melanoma","volume":"23","author":"Vilain","year":"2017","journal-title":"Clin Cancer Res"},{"key":"key20221013104825_b107-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1053\/j.gastro.2017.06.007","article-title":"Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features","volume":"153","author":"Sia","year":"2017","journal-title":"Gastroenterology"},{"key":"key20221013104825_b108-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1111\/liv.13697","article-title":"High number of PD-1 positive intratumoural lymphocytes predicts survival benefit of cytokine-induced killer cells for hepatocellular carcinoma patients","volume":"38","author":"Chang","year":"2018","journal-title":"Liver Int"},{"key":"key20221013104825_b109-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"733530","DOI":"10.3389\/fimmu.2021.733530","article-title":"Viral status and efficacy of immunotherapy in hepatocellular carcinoma: A systematic review with meta-analysis","volume":"12","author":"Ding","year":"2021","journal-title":"Front Immunol"},{"key":"key20221013104825_b110-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"key":"key20221013104825_b111-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s40425-019-0650-9","article-title":"Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma","volume":"7","author":"Zheng","year":"2019","journal-title":"J Immunother Cancer"},{"key":"key20221013104825_b112-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.3390\/ijms20061406","article-title":"Exosomes and hepatocellular carcinoma: From bench to bedside","volume":"20","author":"Sasaki","year":"2019","journal-title":"Int J Mol Sci"},{"key":"key20221013104825_b113-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.3892\/ol.2015.3078","article-title":"Eukaryotic translation initiation factor 3, subunit C is overexpressed and promotes cell proliferation in human glioma U-87 MG cells","volume":"9","author":"Hao","year":"2015","journal-title":"Oncol Lett"},{"key":"key20221013104825_b114-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.omtn.2018.02.014","article-title":"Hepatocellular carcinoma cell-secreted exosomal MicroRNA-210 promotes angiogenesis in vitro and in vivo","volume":"11","author":"Lin","year":"2018","journal-title":"Mol Ther Nucleic Acids"},{"key":"key20221013104825_b115-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1111\/cas.13697","article-title":"Exosomes in cancer development and clinical applications","volume":"109","author":"Tai","year":"2018","journal-title":"Cancer Sci"},{"key":"key20221013104825_b116-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.ebiom.2018.12.062","article-title":"Three isoforms of exosomal circPTGR1 promote hepatocellular carcinoma metastasis via the miR449a-MET pathway","volume":"40","author":"Wang","year":"2019","journal-title":"EBioMedicine"},{"key":"key20221013104825_b117-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"4018","DOI":"10.18632\/oncotarget.26998","article-title":"Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma","volume":"10","author":"Ang","year":"2019","journal-title":"Oncotarget"},{"key":"key20221013104825_b118-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"822449","DOI":"10.3389\/fonc.2022.822449","article-title":"Potential biomarkers for liver cancer diagnosis based on multi-omics strategy","volume":"12","author":"Chen","year":"2022","journal-title":"Front Oncol"},{"key":"key20221013104825_b119-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2147\/JHC.S217948","article-title":"Impact of next-generation sequencing on outcomes in hepatocellular carcinoma: How precise are we really?","volume":"7","author":"Dominguez","year":"2020","journal-title":"J Hepatocell Carcinoma"},{"key":"key20221013104825_b120-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1158\/1078-0432.CCR-18-2293","article-title":"Prospective genotyping of hepatocellular carcinoma: Clinical Implications of next-generation sequencing for matching patients to targeted and immune therapies","volume":"25","author":"Harding","year":"2019","journal-title":"Clin Cancer Res"},{"key":"key20221013104825_b121-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3390\/cancers12010182","article-title":"Predictors of response and survival in immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma","volume":"12","author":"Lee","year":"2020","journal-title":"Cancers (Basel)"},{"key":"key20221013104825_b122-ol-24-05-13530","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.3390\/cancers11111798","article-title":"Tumour mutational burden and efficacy of immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"11","author":"Kim","year":"2019","journal-title":"Cancers (Basel)"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T03:48:56Z","timestamp":1665632936000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2022.13530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,27]]},"references-count":122,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,9,27]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2022.13530","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,27]]},"article-number":"410"}}